Parkinson's disease age at onset genome-wide association study : Defining heritability, genetic loci, and α-synuclein mechanisms by 23andMe Res Team et al.
R E S E A R C H A R T I C L E
Parkinson’s Disease Age at Onset Genome-Wide Association Study:
Deﬁning Heritability, Genetic Loci, and α-Synuclein Mechanisms
Cornelis Blauwendraat, PhD,1,2* Karl Heilbron, PhD,3 Costanza L. Vallerga, MSc,4 Sara Bandres-Ciga, PhD,1
Rainer von Coelln, MD,5 Lasse Pihlstrøm, MD, PhD,6 Javier Simón-Sánchez, PhD,7,8 Claudia Schulte, PhD,7,8
Manu Sharma, PhD,9 Lynne Krohn, MSc,10,11 Ari Siitonen, PhD,12,13 Hirotaka Iwaki, MD, PhD,1,14
Hampton Leonard, MSc,1 Alastair J. Noyce, MD, PhD,15,16 Manuela Tan, BA,16 J. Raphael Gibbs, PhD,1
Dena G. Hernandez, PhD,1 Sonja W. Scholz, MD, PhD,2 Joseph Jankovic, MD,17 Lisa M. Shulman, MD,5
Suzanne Lesage, PhD,18 Jean-Christophe Corvol, MD, PhD,18 Alexis Brice, MD, PhD,18 Jacobus J. van Hilten, MD, PhD,19
JohanMarinus, MD, PhD,19 The 23andMe Research Team, Johanna Eerola-Rautio, MD, PhD,20 Pentti Tienari, MD, PhD,20
Kari Majamaa, MD,12,13 Mathias Toft, MD, PhD,6,21 Donald G. Grosset, MD, PhD,22,23 Thomas Gasser, MD, PhD,7,8
Peter Heutink, PhD,7,8 Joshua M. Shulman, MD, PhD,17,24,25 Nicolas Wood, MD, PhD,16 John Hardy, PhD,26
Huw R. Morris, MD, PhD,16 David A. Hinds, PhD,3 Jacob Gratten, PhD,4,27 Peter M. Visscher, PhD,4,28
Ziv Gan-Or, MD, PhD,10,11,29 Mike A. Nalls, PhD,1,30 and Andrew B. Singleton, PhD,1*
for the International Parkinson’s Disease Genomics Consortium (IPDGC)
1Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA
2NeurodegenerativeDiseasesResearchUnit, National Institute ofNeurological Disorders andStroke,National Institutes ofHealth, Bethesda,Maryland, USA
323andMe, Inc., Mountain View, California, USA
4Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
5Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA
6Department of Neurology, Oslo University Hospital, Oslo, Norway
7Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
8German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
9Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany
10Department of Human Genetics, McGill University, Montreal, Quebec, Canada
11Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
12Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland
13Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland
14The Michael J Fox Foundation for Parkinson’s Research, New York, New York, USA
15Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom
16Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom
17Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
18Inserm U1127, Sorbonne Universités, UPMC Univ Paris 06 UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
19Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
20Department of Neurology, Helsinki University Hospital, andMolecular Neurology, Research ProgramsUnit, Biomedicum, University of Helsinki,
Helsinki, Finland
21Institute of Clinical Medicine, University of Oslo, Oslo, Norway
22Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom
23Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, United Kingdom
24Departments of Molecular & Human Genetics and Neuroscience, Baylor College of Medicine, Houston, Texas, USA
25Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, Texas, USA
26Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom
27Mater Research, Translational Research Institute, Brisbane, Queensland, Australia
28Queensland Brain Institute, The University of Queensland, Brisbane, Australia
29Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada
30Data Tecnica International, Glen Echo, Maryland, USA
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
*Correspondence to:Dr. Cornelis Blauwendraat, Laboratory of Neu-
rogenetics, NIA, NIH, Building 35, 35Convent Drive, Bethesda,MD 20892,
USA; E-mail: cornelis.blauwendraat@nih.gov; or
Dr. Andrew B. Singleton, Laboratory of Neurogenetics, NIA, NIH, Build-
ing 35, 35 Convent Drive, Bethesda, MD 20892, USA; E-mail:
singleta@mail.nih.gov
Received: 30 November 2018; Revised: 2 January 2019; Accepted: 21
January 2019
Authors C.B. and K.H. contributed equally to this work.
Relevant conﬂicts of interest/ﬁnancial disclosures: Nothing to
report.
Full ﬁnancial disclosures and author roles may be found in the online
version of this article.
Published online 00 Month 2019 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.27659
Movement Disorders, 2019 1
ABSTRACT: Background: Increasing evidence supports
an extensive and complex genetic contribution to PD. Previ-
ous genome-wide association studies (GWAS) have shed
light on the genetic basis of risk for this disease. However, the
genetic determinants of PD age at onset are largely unknown.
Objectives: To identify the genetic determinants of PD age
at onset.
Methods: Using genetic data of 28,568 PD cases, we per-
formed a genome-wide association study based on PD age
at onset.
Results: We estimated that the heritability of PD age at
onset attributed to common genetic variation was 0.11,
lower than the overall heritability of risk for PD (0.27), likely,
in part, because of the subjective nature of this measure. We
found two genome-wide signiﬁcant association signals, one
atSNCA and the other a protein-coding variant in TMEM175,
both of which are known PD risk loci and a Bonferroni-
corrected signiﬁcant effect at other known PD risk loci,GBA,
INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. Notably,
SNCA, TMEM175, SCARB2, BAG3, and GBA have all been
shown to be implicated in α-synuclein aggregation path-
ways. Remarkably, other well-established PD risk loci, such
asGCH1 andMAPT, did not show a signiﬁcant effect on age
at onset of PD.
Conclusions: Overall, we have performed the largest age
at onset of PD genome-wide association studies to date,
and our results show that not all PD risk loci inﬂuence age at
onset with signiﬁcant differences between risk alleles for
age at onset. This provides a compelling picture, bothwithin
the context of functional characterization of disease-linked
genetic variability and in deﬁning differences between risk
alleles for age at onset, or frank risk for disease. © 2019
International Parkinson andMovement Disorder Society
Key Words: age at onset; GBA; Parkinson’s disease;
SNCA; TMEM175
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder. PD is pathologically char-
acterized by the loss of dopaminergic neurons in the SN
and α-synuclein (encoded by SNCA) protein aggregates.
Current estimates are that in 2015 there were 6.9 million
PD patients worldwide, and this number is predicted to be
14.2 million in 2040.1 PD has a strong age-dependent
prevalence and male-female differences, where males are
1.5 timesmore likely to develop PD.2,3
The exact cause of PD is unknown; however, there is
clear evidence that genetic variability plays a role in both
disease development and progression. In the past two
decades, mutations in several genes have been identiﬁed
that cause monogenic forms of PD, accounting for around
1% to 5% of all PD cases.4 The majority of PD cases are
therefore referred to as sporadic PD. Genome-wide associ-
ation studies (GWAS) have successfully identiﬁed over
40 loci robustly associated with PD. Interestingly, variabil-
ity in several genes, including SNCA, LRRK2, VPS13C,
GCH1, and GBA, appear to play a role in both mono-
genic and sporadic disease.5
Substantial evidence suggests that genetic variation plays
a role in age at onset (AAO), where, for example, mono-
genic forms of PD often present as early-onset cases, but the
identity of the exact genetic component in sporadic PD
remains unclear.6,7 Additionally, there is some evidence that
AAOmay be different betweenmales and females.8,9Multi-
ple studies have nominated variants and genes of interest,
but replication and large cohort studies are lacking.7,10,11
Additionally, rare coding variants in PD risk genes like
GBA and LRRK2 have been associated with an earlier
AAO.12-17 Currently, the best predictor of PD AAO is a
genetic risk score (GRS) based on cumulative genetic PD
risk,7,18 implying broad genetic overlap between PD suscep-
tibility and PDAAO.
In this study, we performed the largest PD AAO
GWAS to date including 28,568 PD cases. Using this
large cohort, we have estimated the heritability of PD
AAO and have identiﬁed several associated variants.
Additionally, we have shown that the latest PD GRS
remains highly correlated with of AAO.
Materials and Methods
Processing of International Parkinson’s
Disease Genomics Consortium Data Sets
Genotyping data (all Illumina platform based) were
obtained from International Parkinson’s Disease Geno-
mics Consortium (IPDGC) members, collaborators, and
public resources (Supporting Information Table S1). All
data sets underwent quality control separately, both on
individual-level data and variant-level data, before impu-
tation. See Supporting InformationMethods for a detailed
description of data processing. Where possible, AAO was
deﬁned based on patient report of initial manifestation of
parkinsonian motor signs (tremor, bradykinesia, rigidity,
or gait impairment). Where this information was not
available, age of diagnosis was used as a proxy for onset
age. Note that the correlation was high between age of
diagnosis and AAO.
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The resulting quality-controlled and imputed data sets
of PD cases (total n = 17,415) were analyzed with the for-
mula AGE_AT_ONSET  SNP + SEX + PC1-PC5. Ana-
lyses were performed per data set with rvtests linear
regression using imputed dosages.19 System Genomics of
Parkinson’s Disease (SGPD) data (n = 581) was processed
as above with the following minor changes: A linear
regression model in PLINK was used to run a GWAS for
AAO, and relatedness cutoff of 0.05 was used. The associ-
ation analysis was adjusted for sex and the ﬁrst 10 eigen-
vectors from principal component analysis.
Processing of the 23andMe Data Set
As an independent second cohort, we used the 23andMe
PD data set (n = 10,572), which consisted of customers of
the personal genetics company, 23andMe, Inc., who had
consented to participate in research. PD patients were rec-
ruited through a targeted e-mail campaign in conjunction
with the Michael J. Fox Foundation or other partners,
patient groups, and clinics. PD cases were individuals who
self-reported having been diagnosed with PD and who self-
reported their age of PD diagnosis. We used age of diagno-
sis rather than age of symptom onset because symptom
onset is often gradual and may be more difﬁcult to self-
report accurately. Note that the correlation was high
between age of diagnosis and AAO (ρ = 0.917; P < 1E-300),
and the average difference between age of diagnosis and
AAO was 2.58 years. We have previously shown that self-
reported PD case status is accurate with 50 of 50 cases
conﬁrmed by telemedicine interview.20 See Supporting
Information Methods for a detailed description of data
processing. After quality control, which included R2 > 0.5
variant removal, we analyzed 11,956,580 single-nucleotide
polymorphisms (SNPs). Remaining PD cases (n = 10,572)
were analyzed using the formula AGE_AT_DIAGNOSIS
SNP + SEX + PC1-PC5 + genotyping platform. The geno-
mic inﬂation factor was λ = 1.015.
Meta-Analyzing Data Set
The 17 IPDGC data sets were meta-analyzed using
METAL (v.2011-03-25) ﬁxed effects using default set-
tings.21 We excluded SNPs with an I2 statistic >50% and
variants that were present in fewer than 66.7% of the data
sets. One genome-wide signiﬁcant variant was excluded
because of this ﬁlter criteria (rs2737029, I2 = 58.1%). This
resulted in a total of 6,850,647 variants and a genomic
inﬂation factor of λ = 1.001. For the combined GWAS,
we meta-analyzed all 17 IPDGC data sets with the
23andMe data set using the same quality-control steps.
Additional Analyses and Figures
PD GWAS loci were obtained from using Table 1 and
Table 2 of Chang et al 20175 and using P.META from the
provided summary stats (see Supporting Information
Table S3). Additionally, to assess the inﬂuence of a GRS for
PD case-control status on PD AAO, we obtained the GRS
from the most recent PD GWAS Supplementary.5 The GRS
was calculated and processed using PLINK for each individ-
ual as described previously.7 Associations were performed
using the formula AGE_AT_ONSET  GRS + SEX +
PC1-PC5. Quantile-quantile (QQ)-plots and Manhattan
plots were generated using FUMA.22 Forest plots were gen-
erated in R using the package rmeta (https://cran.r-project.
org/web/packages/rmeta/index.html). Locus plots23 were
generated for the genome-wide signiﬁcant loci and were
compared to the latest published PD GWAS.5 GCTA-cojo
analyseswere performed to identifywhether thereweremul-
tiple independent signals in loci of interest using all IPDGC
data sets (excluding SGPD) described in Supporting
Infromation Table S1 as a reference panel.24,25 This refer-
ence panel was created using variants passing the following
criteria: R2 < 0.8, minor allele frequency >0.001, Hardy-
Weinberg equilibrium P < 1E-6, and a maximum variant
missingness of 5%. The genetic correlation between the PD
AAOGWAS and the PDGWAS5 was calculated using link-
age disequilibrium score regression (LDSC)26 using default
settings for European populations. Heritability was esti-
mated using LDSC and GCTA based on GWAS summary
statistics and individual-level genotypes, respectively.
Power Calculations
We performed power calculations using the method
of Brion and colleagues:27
Power = 1−P χ2NCP > χ
2
0:95
 
where χ2NCP is a random variable from a noncentral χ
2
with one degree of freedom, and χ20:95 is the threshold of a
central χ2distribution with one degree of freedom and a
type 1 error rate of 0.05. The noncentrality parameter
was calculated using the method of Sham and Purcell:28
λ =N ×
2p 1−pð Þ× β2
variance Yð Þ
where λ is the noncentrality parameter, p is theminor allele
frequency, β is the effect size in years, and variance(Y) is
the variance in PDAAO.We estimated variance(Y) by tak-
ing the mean variance across each cohort, weighted by
their sample size. We assessed effect sizes between 0.01
and 1 years and reported the minimum effect size that
yielded >80%power.
RESULTS
Initial Data Overview
In total, we included 18 data sets: the IPDGCdata contain
17 independent cohorts (n = 17,996) and the 23andMe PD
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cohort (n = 10,572; see Supporting Information Table S1
for more details). The average AAO in the IPDGC data set
was 62.14 (range, 20–96; standard deviation [SD] = 12.08),
whereas in the 23andMe dataset the average age of diagno-
sis was 60.71 (range, 40–97; SD = 9.98). We found minor
differences in AAO in females andmales in both the IPDGC
data set (females = 62.15, SD = 11.71; males = 62.03,
SD = 11.95) and the 23andMe data set (females = 59.95,
SD = 9.79;males = 61.20, SD =10.07).
Heritability of PD Age at Onset
Using LDSC, the heritability of PD AAOwas h2 = 0.076
(standard error [SE] = 0.0277) in the IPDGC cohort,
h2 = 0.0805 (SE = 0.0403) in the 23andMe cohort, and
0.109 (SE = 0.0255) in the complete meta-analysis. These
heritability estimates for PDAAOwere similar to estimates
derived using GCTA in the largest IPDGC data set
(IPDGC_NeuroX, h2 = 0.0798; SE = 0.0391; P = 0.0184;
N = 5,428) and in the 23andMe dataset (h2 = 0.1235;
SE = 0.0341; P = 1.031E-4; N = 10,697). Heritability esti-
mates in the other IPDGC data sets were considered less
reliable because of the low number of included cases.
SNCA as Top Associated Loci
With PD Age at Onset
Two loci reached genome-wide signiﬁcance, SNCA and
TMEM175, both of which are established PD risk loci
based on PD case/control GWASes (Fig. 1). Common vari-
ation at the SNCA locus has clearly been established as a
risk factor PD, and both rare mutations and whole-gene
multiplications have been identiﬁed to cause monogenic
PD.29,30 Several independent signals have been reported in
this locus, where initially a variant in intron 4was identiﬁed
in PD;31 subsequently a second independent signal at the 50
endwas identiﬁed,32which is also associatedwith dementia
with Lewy bodies;33 and currently at least three indepen-
dent signals are present in this locus.34 Here, we identiﬁed
both signals to be associated with AAO (Fig. 2A). The 30
end signal is the strongestwith rs356203 as themost associ-
ated SNP, resulting in a reduction of 0.6 year in AAO
(P_meta = 1.90E-12; beta = –0.626; SE = 0.0890). Using
conditional analysis, we also identiﬁed the 50 end signal
(Fig. 2B; rs983361, P_conditional = 6.82E-6; beta = –0.484;
SE = 0.108).
A Coding Variant in TMEM175 Is Associated
With PD Age at Onset
The TMEM175/GAK locus is another known PD locus
where two independent signals have been identiﬁed.32
Whereas it is more parsimonious to assume that a single
GWAS peak is the product of a single causal gene in the
locus, there is evidence that both TMEM175 and GAK
may modulate PD risk.35,36 TMEM175 and GAK share
a promoter, suggesting that they may be coregulated and
may perform related cellular functions. Interestingly, the
TMEM175/GAK locus is one of the few PD GWAS loci
where a coding variant (TMEM175 p.M393 T, exon
11, rs34311866) is among the highest associated variants
(Fig. 2A). This coding variant was also the most associated
variant in this locus in our PD AAO analysis (P_meta =
9.62E-9; beta = –0.613; SE = 0.107), resulting in an
average reduction of 0.6 years (Figs. 3B and 5). Using
conditional analysis based on rs34311866, we did
not identify a second independent signal in this locus
(P = 0.879; beta = –0.0240; SE = 0.158; Supporting Infor-
mation Fig. S9).
PD High-Risk Variants in GBA and LRRK2
and Age at Onset
LRRK2 p.G2019S andGBA variants are the most com-
monly identiﬁed genetic risk factors for PD. LRRK2
p.G2019S is identiﬁed in 1% of the general European
PD population, but higher frequencies have been reported
in other populations.37GBA variants are more commonly
identiﬁed in Ashkenazi Jewish populations, but are also
present in the European population.38
LRRK2 p.G2019S (rs34637584) has already been
described to have a large range of AAO and reduced pene-
trance.12,14 Because of the low frequency and low imputa-
tion quality of this variant, it did not pass the variant-level
quality control and was only tested in 9 of the 18 data sets.
Similar to previous studies,37 we identiﬁed 140 carriers in
the IPDGC data sets (0.8% of all PD cases). The average
AAO for p.G2019S carriers was 66.58 (range = 36–95;
SD = 11.66), which is4 years later compared to the aver-
age AAO of noncarriers in the IPDGC data sets (62.14;
range, 20–96; SD = 12.08). However, this is based on a rel-
atively small amount of cases, and some cohorts excluded
LRRK2 p.G2019S carriers pregenotyping or excluded
familial PD cases. Besides, the noncoding variant at the 50
end of LRRK2 (rs76904798), which is also identiﬁed as a
risk factor PD did not show an association with AAO
(P = 0.1267; beta = –0.184; SE = 0.121).
For GBA, there have been several reports that variants
in GBA affect AAO in PD.39-41 When solely looking at
the GBA locus, we identiﬁed three signiﬁcant hits for
the GBA region including p.N370S variant (rs76763715,
P = 2.628E-6; beta = –2.600; SE = 0.553), p.E326K
(rs2230288, P = 0.00123; beta = –0.929; SE = 0.287 and
p.T369M (rs75548401: P = 0.01153; beta = –1.281; SE =
0.507). All resulted in relatively large reduction AAO rang-
ing from of 2.6 to 0.9 year. Note that the p.N370S variant
was only tested in 13 of the 18 data sets because of the low
frequency or low imputation quality. Using conditional
analysis, we did not identify other clear signiﬁcant signals
in theGBA gene (Supporting Information Fig. S11).
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PD Genetic Risk Loci Are Associated
With Age at Onset
Previously, a GRS based on PD GWAS loci has been
identiﬁed as the main genetic predictor for AAO.7 Here, we
tested the association between the updated 47-SNP GRS
used in the latest PD GWAS study.5 For each IPDGC data
set, the GRS was calculated and we identiﬁed a consistent
association between the Chang and colleagues GRS and PD
AAO. After meta-analyzing results from the individual
cohorts, we found that each 1-SD increase in GRS led to
an earlier AAO by 0.8 years (summary effect = –0.801;
95% conﬁdence interval CI: –0.959, –0.643; I2 = 11.6%;
Supporting Information Fig. S12). Although this effect was
highly signiﬁcant, the genetic proportion explained by the
GRS was 0.56%, and the SNCA and TMEM175 loci
combined explained 0.3%, most likely attributed to the
lower heritability. Furthermore, there was a signiﬁcantly
negative genetic correlation between the AAOGWAS sum-
mary statistics and the most recent PDGWAS5 using LDSC
(rg = –0.5511; se = 0.103;P = 9.027E-8).
When solely looking at the SNPs that were genome-wide
signiﬁcant in the most recent PD GWAS,5 we identiﬁed a
signiﬁcant effect in six loci after Bonferroni correction:
SNCA, TMEM175, BST1, INPP5F/BAG3, FAM47E/
SCARB2, and MCCC1 (Fig. 4; Supporting Information
Table S3). Interestingly, for some well-established loci, no
signiﬁcant P values were identiﬁed in any of the data sets,
including GCH1 (P_meta = 0.9769; 80% power to detect
FIG. 1. Manhattan plot of Parkinson’s disease age at onset GWAS. Based on meta-analyses of data sets (n = 28,568) using 7,426,111 SNPs. Two
genome-wide signiﬁcant loci were identiﬁed: SNCA and the TMEM175/GAK. Additionally, one borderline signiﬁcant locus was found, APOE. [Color ﬁg-
ure can be viewed at wileyonlinelibrary.com]
FIG. 2. SNCA association with Parkinson’s disease age at onset. (A) Locus zoom plot of the association signal of the SNCA locus. The age at onset
association signal is primarily based at the 3’ end of the SNCA gene, highly similar as the PD GWAS signal of Chang and colleagues5 (Supporting Infor-
mation Fig. S8). (B) Conditional analysis based on the most associated SNP (rs356203) shows that there is a secondary signal at the 5’ end of the
SNCA gene rs6532192, as well similar as previously reported for the PD GWAS.5 [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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a change in AOO >0.28 years), RAB7L1/NUCKS1
(PARK16; P_meta = 0.124; 80% power to detect a change
in AOO >0.26 years), and MAPT (P_meta = 0.745; 80%
power to detect a change in AOO >0.32 years; Fig. 5; see
Supporting InformationTable S3 for all power calculations).
APOE E4 Allele as Positive Control
Longevity Marker
Interestingly, the variant representing theAPOE E4 allele
(rs429358) was among the borderline signiﬁcant loci with
a P_meta value of 5.696E-8 resulting in a 0.7 year earlier
of AAO (beta = –0.707; SE = 0.130). The APOE E4 allele
is the most common genetic risk factor for Alzheimer’s
disease,42 but has no effect on PD (P value in latest
GWAS = 0.625).32,43 Interestingly, it has already been pre-
viously identiﬁed as an aging marker.44,45 To investigate
this in our data, we performed a GWAS on the reported
age of controls from the IPDGC data sets and this demon-
strated a result consistent with that observed in the PD
cases: P value of 1.49E-5 (effect = –0.644; SE = 0.149),
suggesting that associations observed at this locus are gen-
eral age-related effects (Fig. 5). Conditional tests based on
rs429358 showed that the whole signal is coming from
the APOE E4 allele (Supporting Information Fig. S10).
FIG. 3. TMEM175/GAK locus association with Parkinson’s disease age at onset and Parkinson’s disease. (A) Locus zoom plot of the association signal of the
TMEM175/GAK locus with PD age at onset. The association signal is primarily based on the coding variant TMEM175 p.M393T, rs34311866. (B) Locus zoom
plot of the association signal of the TMEM175/GAK locuswith PD versus controls.5 Similarly, as in (A), themain signal is based on the coding variant TMEM175
p.M393 T, rs34311866. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
FIG. 4. P-value and beta-value correlation plot between Parkinson’s disease GWAS and age at onset GWAS. (A) Log-transformed P values were plot-
ted of the Chang and collegaues5 PD GWAS (x-axis) and the current age at onset GWAS (y-axis). SNPs are annotated by their closest gene. Green dots
are loci that pass Bonferroni correction and red are loci that did not pass Bonferroni correction. (B) Beta values were plotted of the Chang and col-
leagues5 PD GWAS (x-axis) and the current age at onset GWAS (y-axis). SNPs are annotated by their closest gene. Green dots are loci that pass
Bonferroni correction, and red are loci that did not pass Bonferroni correction. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Additionally, none of the PD loci in the control dataset
had a signiﬁcant P value after correction for multiple test-
ing (Supporting Information Table S5).
Replication of Previous Associated Loci
and Potential Sex Effects
In the past decade, several studies have performed PD
AAO analyses and nominated many genes and variants of
interest (Supporting Information Table S2). Many of these
variants and genes were identiﬁed in smaller data sets and
were reported with nominal P values or could not be repli-
cated in other data sets. In our current GWAS, we replicate
the ﬁndings in SNCA,GBA, and TMEM175 as described
above (Supporting Information Table S2).
Additionally, some evidence exists there that there might
be sex differences in AAO. To investigate this, we divided
the IPDGC data sets (excluding the SGPD data set) into a
males-only data set (N = 11,411) and a females-only data
set (N = 6,621) and performed sex-speciﬁc AAO GWASes
and meta-analyses. No genome wide-signiﬁcant hits were
identiﬁed in either the male or the female meta-analysis, and
the effect sizes for themost recent PDGWASvariantsChang
and colleagues were similar (Pearson correlation = 0.532;
P = 0.00034; Supporting Information Table S4). Interest-
ingly, we did identify a similar sex-speciﬁc effect of the
COMT coding variant rs4680 (p.V158M) as reported pre-
viously: P = 0.0133 in males (effect = 0.370; SE = 0.150)
andP = 0.922 in females (effect = –0.0188; SE = 0.193).46
Discussion
Here, we performed a genome-wide AAO analysis
using 28,568 PD cases and discovered several PD loci
associated with AAO. We identiﬁed two genome-wide
signiﬁcantly associated loci—SNCA (P_meta = 1.90E-12)
and TMEM175 (P_meta = 9.62E-9)—as well as several
subsigniﬁcant loci including GBA, SCARB2, and BAG3.
Notably, this is the ﬁrst study reporting genome-wide
signiﬁcance for PD GWAS loci for PD AAO. The herita-
bility estimate of PD AAO was 0.11, which is much
less than the heritability of PD case-control status
0.27.5,47 Our heritability estimate was lower than an
FIG. 5. Minor allele frequency differences correlated with age groups separated by case-control status. Genotype data were merged and minor allele fre-
quency was calculated per age group and separated by case-control status (IPDGC data only: N_cases = 17,996 and N_controls = 16,502; each age group
contains >850 individuals). Lines were using LOESS regressions based on the minor allele frequency per age group. On the left, the three most signiﬁcant loci
associated with PD age at onset are shown; SNCA = rs356203, TMEM175/GAK = rs34311866, and APOE = rs429358. On the right, three signiﬁcant PD
case-control GWAS loci are shown to have no clear effect on PD age at onset; MAPT = rs17649553, RAB7L1 = rs823118, and GCH1 = rs11158026.
Standard-error bars are not shown in the ﬁgure, but are neglectable (~0.015) for each age group. LOESS, locally estimated scatterplot smoothing. [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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estimate from a previous study in familial PD, although
this was based on a relatively small data set (n = 504
families).6 This is likely, in large part, attributed to the
subjective nature of this phenotype.
It has been shown that PD case-control GWAS loci are
associated with PD AAO.7 We found that a GRS based on
the latest PD GWAS5 was also highly associated with an
earlier age of PD onset (Supplementary Figure 12). Further-
more, there was a signiﬁcant negative genetic correlation
between the PD case-control GWAS and the PD AAO
GWAS. Six individual loci remained signiﬁcant after
Bonferroni correction, including two well-established PD
loci—SNCA and TMEM175—and four less-studied PD
loci—BST1, INPP5F/BAG3, FAM47E/SCARB2, and
MCCC1. Interestingly, no effect was identiﬁed for several
well-established loci, including GCH1, RAB7L1
(PARK16), and MAPT (Supporting Information Table
S3). For these three loci, our study had 80% power
(at P = 0.05) to detect changes greater than 0.28, 0.26, and
0.32 years, respectively. For comparison, the two genome-
wide signiﬁcant hits in SNCA and TMEM175 modiﬁed
AAO by ~0.6 year. We believe this provides compelling
evidence that only a subset of PD case-control risk SNPs
also modulates PD AAO, and notably that variability at
MAPT, a major GWAS identiﬁed risk factor for PD, does
not inﬂuence AAO.We believe these data may suggest that
different PD loci modulate risk through different pathways
and that this likely has therapeutic consequences.
Interestingly, three of our top hits (SNCA, TMEM175,
and GBA) are strongly implicated in α-synuclein mecha-
nisms of PD pathogenesis pathology. SNCA encodes for
the α-synuclein protein, which is the major constituent of
Lewy bodies, the deﬁning pathology of PD. Both common
and rare variants at SNCA are associated with increased
PD risk, including duplications or triplications of the
genomic locus.29 One of the distinguishing features of
autosomal-dominant PD caused by SNCA gene multiplica-
tions is an early AAO.48,49 The common variants at SNCA
associated with PD risk and AAO have also been demon-
strated to enhance SNCA gene expression.34,50 Thus, based
on the genetics of bothMendelian and sporadic PD, SNCA
dosage appears to be a major driver of disease onset age.
TMEM175 has been shown to impair lysosomal and mito-
chondrial function and increases α-synuclein aggregation.36
GBA has been shown to be involved in several α-synuclein
aggregationmechanisms, including autophagy and enhanc-
ing α-synuclein cell-to-cell transmission.51–-53 Other loci
identiﬁed by our PDAAO analyses have also been linked to
α-synuclein clearance, for example for SCARB2, encoding
the endoplasmic reticulum–to-lysosome transporter of
GBA, and BAG3.54,55 Taken together, it is tempting
to speculate about the direct link between PD AAO
loci inﬂuencing α-synuclein accumulation and clearance
pathways and the other nonsigniﬁcant PD loci acting in
another pathway by a different mechanism, but more
experiments are needed to conﬁrm this.
Several previous studies have performedPDAAOanalyses
in smaller data sets.Wewere unable to replicate themajority
of these previous reported variants, likely because of the lack
of power to detect a true signal in the smaller studies (<2,000
samples; see Supporting Information Table S2). We may
have been unable to replicate previous work by Hill-Burns
and colleagues, given that much of their analysis was
restricted to familial PD cases.11 Their analysis of sporadic
PD included almost 4,000 cases, but unlike our study
and several others,7,40,56 they did not ﬁnd signiﬁcant associa-
tions with SNCA (rs356203, P = 0.355) or TMEM175
(rs34311866,P = 0.525).
Although we included a very large amount of data, there
were still several limitations to our study. First, we had lim-
ited power to detect rare variants that modulate PD AAO
because of the use of genotyping arrays and large number
of cohorts with a relatively small size. Several reports have
shown that rare variants may inﬂuence AAO of PD. For
example, a recent report showed that rare variants in
LRRK2 lowered AAO.16 This likely also explains the rela-
tively moderate P values for rare coding variants in GBA
andLRRK2 on age onset.
Second, because of the lack of reliable genotype data, we
excluded chromosomes X and Y from our analysis. Both of
these limitations could be addressed by using genome
sequencing data, and large genome sequencing projects are
currently underway. Third, the heritability of PD AAO
(0.11) was much lower than the heritability of PD case-
control status,47 which, in part, explains the lack of genome-
wide signiﬁcantly associated loci in our study. Fourth, there
was a reasonable amount of heterogeneity in themeanAAO
our different cohorts. Age of PD diagnosis was self-reported
in some of our cohorts and assessed by physicians in other
cohorts. Some cohorts were speciﬁcally designed to include
younger-onset cases. Other cohorts provided age of diagno-
sis whereas others used AAO, although these are likely to be
highly correlated (r > 0.9 in our data). By analyzing each
cohort separately, we were able to mitigate many of these
interstudy sources of variation. Indeed, there was relatively
little heterogeneity of SNP effect-size estimates between stud-
ies (Supporting Information Table S3). However, future
data collection and studies would probably beneﬁt from
more speciﬁc andmore predeﬁned structured and symptom-
speciﬁc AAO diagnostic criteria. Implementation of such
criteria in large studies and cohorts or even in health care
systems could signiﬁcantly improve the understanding of
the genetics of PDAAO.
Overall, we have performed the largest AAOof PDGWAS
to date, and our results reveal an interesting and signiﬁcant
genetic component. Our results show that not all PD risk loci
inﬂuence AAO with signiﬁcant differences between risk
alleles for AAO, which implies different mechanisms for risk
for developing PD and PDAAO. This provides a compelling
picture, both within the context of functional characteriza-
tion of disease-linked genetic variability and in deﬁning dif-
ferences between risk alleles for AAO, or frank risk for
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disease. The signiﬁcantly associated variability is centered on
the gene encoding α-synuclein and on variability in several
other lysosomal proteins that have been shown to directly
inﬂuence α-synuclein aggregation or clearance. Thus, these
data support the notion that α-synuclein is an important tar-
get for future disease-modifying or -preventive therapies and
that drugs targeting α-synuclein production and clearance
may bemost valuable.
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